MaxCyte Establishes New Scientific Advisory Board Comprised

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the formation of its new Scientific Advisory Board (SAB) that will reflect the cutting edge of research in molecular design and cell engineering, as well as a deep understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications.

“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte. “These four dynamic scientists are deeply connected in the scientific community through their work and memberships in professional societies and will bring the innovation and support needed to nurture our early-stage projects from beginning to end.”

Each of these individuals has a unique background and brings a diverse scientific perspective. Supported by deep technical knowledge, the SAB will help us unlock the power of cells, which will enhance our R&D activities and portfolio,” said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte. “With the SAB’s guidance, we aim to provide our clients with innovative cell engineering applications that accelerate the development of novel therapies to improve patient outcomes.”

Members of the MaxCyte Scientific Advisory Board include:

Oliver Rando, MD, PhD, is a professor in the Biochemistry and Molecular Biotechnology Department at the University of Massachusetts Worcester T.H. Chan School of Medicine and principal investigator within the Rando Lab, which is focused on genomic approaches to chromatin structure and function, as well as epigenetic inheritance. He completed his PhD and MD at Stanford University in Palo Alto, California, working on chromatin remodeling and T-cell activation in the lab of Jerry Crabtree. Dr. Rando received a Bachelor of Arts in Biochemistry from Harvard University in Cambridge, Massachusetts while working on the role of the proteasome in activation of NF-kB in the lab of Tom Maniatis.

Marcela Maus, MD, PhD, FABIM, is an associate professor of medicine at Harvard Medical School and the director of Cellular Immunotherapy at Massachusetts General Hospital Cancer Center. She oversees the Maus Lab, which evaluates next-generation, genetically modified CAR T-cells as immunotherapy in patients with hematologic malignancies and solid tumors. Dr. Maus holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania, where she completed graduate training with Dr. Carl June. Dr. Maus then trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. She also received a BS in Biology and Literature from Massachusetts Institute of Technology.

Avery Posey, PhD, is an assistant professor in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Perelman School of Medicine. The Posey Lab focuses on the development of novel targets for CAR-T cell therapies, strategies to enhance the functional persistence of CAR-T cells, and the impact of changes in glycosylation on the tumor immune microenvironment. Dr. Posey holds a PhD in Genetics from the University of Chicago, and two BS degrees in Biochemistry and Bioinformatics from the University of Maryland, Baltimore County (UMBC). He completed his postdoctoral training in the laboratory of Carl June, where he generated glycosylation-specific chimeric antigen receptors to precisely target tumor-glycoforms of MUC1.

Nako Nakatsuka, PhD is a senior scientist/principal investigator in the Laboratory of Biosensors and Bioelectronics at ETH Zurich in Switzerland, whose research is focused on harnessing artificial DNA-based receptors called aptamers for small-molecule biosensing. Aptamers are integrated into nanoscale biosensors to monitor neurotransmitters with the goal of unraveling the basic mechanisms of neurodegenerative diseases. Beyond neuroscience, novel aptamer-based biosensors are being developed with the vision of translation for personalized medicine. Dr. Nakatsuka completed her PhD in Chemistry at the University of California, Los Angeles, while working in the labs of Anne Andrews and Paul Weiss. Her thesis exploited aptamers to overcome the conventional bottlenecks of electronic biosensing of small molecules in complex biological environments. She also joined the bionanotechnology research lab of Professor Ipsita Banerjee at Fordham University in New York while completing her BS degree in Chemistry.

About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at and follow us on Twitter and LinkedIn.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
[email protected]

US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
[email protected]

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
[email protected]

MaxCyte Establishes New Scientific Advisory Board Comprised


AMD to Present at Morgan Stanley’s Technology, Media and

SANTA CLARA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that Mark Papermaster, chief technology officer and executive...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Cellbox Solutions Raises EUR 6.5 Million in Series A1

- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of...

Amid Global Health Worker Shortage, CGFNS Assembles Board

PHILADELPHIA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- With a global health worker shortage accelerating the demand for internationally educated nurses in...

mdf commerce announces a change to its Board of Directors

MONTRÉAL, March 02, 2023 (GLOBE NEWSWIRE) -- mdf commerce inc. (“mdf commerce” or the “Corporation”) (TSX:MDF), a SaaS leader in digital commerce...

Small Pharma to Host Virtual Roundtable Event with Key

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company...

05/2023 Green Hydrogen Systems announces changes to its

Company announcement 05/2023 Green Hydrogen Systems announces changes to its Board of Directors Kolding, Denmark, 1 March 2023 – In connection with...

Terrestrial Energy establishes nuclear technology

Calgary, Alberta, March 07, 2023 (GLOBE NEWSWIRE) -- Terrestrial Energy, a Canadian nuclear technology company dedicated to delivering reliable,...


Cách đồng bộ hóa dữ liệu Y tế iCloud trong iOS 11

Bây giờ, Apple cho phép bạn đồng bộ dữ liệu sức khỏe của bạn ở iCloud trong iOS 11 trên iPhone và iPad.

Cách chơi game Liên quân Mobile trên máy tính

Chơi game Liên quân Mobile trên máy tính hay nói cách khác là cài đặt game Liên quân Mobile và chơi trên một trong những giả lập Android đang phổ biến trên thị trường hiện nay.

Hướng dẫn tăng tốc độ Internet trong Windows 10 version 1709

Hầu hết các bản cập nhật Windows 10 đều từ vài trăm MB đến GB, và đa số người dùng đều phàn nàn rằng kết nối internet của họ sẽ trở nên quá chậm khi Windows Update đang tải về bản cập nhật.

Cách khám phá vũ trụ và hệ mặt trời trên Google Maps

Google Maps mới cho phép người dùng thám hiểm vũ trụ, khám phá hệ mặt trời ngay trên chiếc máy tính của mình. Giờ đây việc xem Mặt trăng, Trái đất, sao Hỏa, Sao Kim, Sao Diêm Vương ngay trên Google Maps không còn là

Hướng dẫn làm USB Boot chuẩn Legacy và UEFI với DLCBoot 2017 v3.4

Dù bạn là một kỹ thuật viên máy tính hay sửa Windows dạo, hoặc chỉ đơn thuần là người thích vọc vạch thì USB cứu hộ vẫn là một thứ không thể thiếu được. Hôm nay, TECHRUM sẽ hướng dẫn các bạn cách để tạo một chiếc USB


HP LaserJet Pro MFP M130nw: giải pháp in ấn tiết kiệm cho doanh nghiệp

Lựa chọn một chiếc máy in cho văn phòng hoặc gia đình là một vấn đề nhiều người quan tâm đến. Trong đó đối tượng khách hàng doanh nghiệp thì yếu tố giá thành và tính năng được đặt lên hàng đầu. Nếu như ‘hầu bao’ của

Điện thoại giá rẻ Samsung Galaxy A03 và những điểm cần lưu ý

Galaxy A03 – mẫu smartphone tích hợp những công nghệ tốt nhất trong phân khúc với Bộ đôi camera 48MP sắc nét, camera xóa phông nghệ thuật và bộ lọc phong phú mở rộng giới hạn sáng tạo của giới trẻ. Bên cạnh đó, dung